Clinical Trial

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
Protocol Amendment History 1 change
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-17
Trial Details
NCT Number NCT07225556
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 84 participants
Start Date 2025-11-18
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16